Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Lab Haematol ; 22(1): 41-4, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10762303

RESUMO

Gastrointestinal mucormycosis is a rare, often fatal, systemic infection found predominantly in immunocompromised patients. We report a case of gastrointestinal mucormycosis in a 53-year-old female with non-Hodgkin's lymphoma. Following her first course of chemotherapy, bowel obstruction developed as a result of mucormycosis. Despite treatment with antifungal therapy, she required a laparotomy owing to severe haemorrhage caused by mucormycosal invasion of her iliac artery. With continued antifungal treatment and further chemotherapy, she ultimately underwent reversal of her Hartmann's procedure and remains disease-free.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Gastroenteropatias/microbiologia , Fístula Intestinal/terapia , Linfoma não Hodgkin/microbiologia , Mucormicose/complicações , Mucormicose/etiologia , Fístula Vascular/terapia , Anfotericina B/administração & dosagem , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Ciclofosfamida/efeitos adversos , Ciclofosfamida/uso terapêutico , Intervalo Livre de Doença , Doxorrubicina/efeitos adversos , Doxorrubicina/uso terapêutico , Feminino , Gastroenteropatias/terapia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/administração & dosagem , Hemorragia/etiologia , Hemorragia/cirurgia , Humanos , Artéria Ilíaca/patologia , Artéria Ilíaca/cirurgia , Hospedeiro Imunocomprometido , Fístula Intestinal/microbiologia , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/tratamento farmacológico , Pessoa de Meia-Idade , Mucormicose/terapia , Prednisolona/efeitos adversos , Prednisolona/uso terapêutico , Fístula Vascular/microbiologia , Vincristina/efeitos adversos , Vincristina/uso terapêutico
2.
Lancet ; 341(8840): 259-65, 1993 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-8093915

RESUMO

Low-molecular-weight heparin (LMWH) is effective in the prevention of postoperative venous thromboembolism but does it have the safety advantages over standard heparin (SH) that have been claimed? In a multicentre randomised trial in 3809 patients undergoing major abdominal surgery (1894 LMWH, 1915 SH) heparin was given preoperatively and continued for at least 5 postoperative days. Patients were assessed in the postoperative period and were followed up for at least 4 weeks, the emphasis being on safety. Major bleeding events occurred in 69 (3.6%) patients in the LMWH group and 91 (4.8%) patients in the SH group (relative risk 0.77, 95% confidence interval 0.56-1.04; p = 0.10). 93 indices of major bleeding were observed in the 69 LMWH patients and 141 in the SH patients. (p = 0.058). Severe bleeding was less frequent in the LMWH group (1.0% vs 1.9%; p = 0.02), as was wound haematoma (1.4% vs 2.7%; p = 0.007). Bleeding episodes with LMWH were less likely to lead to further surgery to evacuate a haematoma or to control bleeding, and injection site bruising was also less common in the LMWH group. No significant differences were found in the efficacy of the two agents. Perioperative death rates were 3.3% in the LMWH group and 2.5% in the SH group; pulmonary emboli were detected in 0.7% and 0.7%; and deep-vein thrombosis was diagnosed in 0.6% of patients in each group. Follow-up was done on 91% of 3699 evaluable patients. There were 19 further deaths (10 LMWH, 9 SH group) and 25 patients with thromboembolic complications (15 and 10). Of the 3 patients with fatal pulmonary emboli during follow-up 2 had received LMWH and 1 SH. The two drugs were of similar efficacy. The primary end point, the frequency of major bleeding, showed a 23% reduction in the LMWH group, but this difference was not significant. The secondary safety end points revealed that LMWH was significantly better than SH. Fatal pulmonary embolism occurs rarely (0.09%) following discharge from hospital so the cost benefit ratio would not justify prolonged prophylaxis in this setting.


Assuntos
Abdome/cirurgia , Heparina de Baixo Peso Molecular/uso terapêutico , Heparina/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Tromboembolia/prevenção & controle , Adulto , Idoso , Distribuição de Qui-Quadrado , Método Duplo-Cego , Feminino , Seguimentos , Hemorragia/induzido quimicamente , Hemorragia/epidemiologia , Heparina/efeitos adversos , Heparina de Baixo Peso Molecular/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/mortalidade , Fatores de Risco , Tromboembolia/epidemiologia , Tromboembolia/mortalidade
4.
Br J Urol ; 61(3): 234-8, 1988 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-3359129

RESUMO

We have reviewed 500 consecutive prostatectomies with a follow-up period of between 5 and 8 years; 184 surviving patients were sent a questionnaire and patients with residual urinary symptoms were interviewed, examined and a flow rate was performed. The operative mortality rate was 0.5%. Patients who presented with retention of urine had a high mortality rate in the first 3 years after the operation. Thirty-six per cent of surviving patients with chronic retention and 24% of those who underwent elective prostatectomy had residual urinary symptoms at the time of the study. Of patients who were sexually active pre-operatively, 34% felt that the operation was responsible for a deterioration in their sex lives. The incidence of retrograde ejaculation was 93%. It was concluded that prostatectomy is a safe operation with good patient acceptability. Patients with symptoms of prostatism require careful evaluation before prostatectomy and sexually active patients should be warned of the risks of impotence and decreased satisfaction due to retrograde ejaculation.


Assuntos
Prostatectomia , Doenças Prostáticas/cirurgia , Fatores Etários , Idoso , Atitude Frente a Saúde , Causas de Morte , Comportamento do Consumidor , Disfunção Erétil/etiologia , Seguimentos , Humanos , Masculino , Complicações Pós-Operatórias , Prostatectomia/efeitos adversos , Prostatectomia/psicologia , Doenças Prostáticas/complicações , Doenças Prostáticas/mortalidade , Doenças Prostáticas/psicologia , Transtornos Urinários/etiologia
5.
J Clin Pathol ; 27(4): 308-10, 1974 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-4851403

RESUMO

A 61-year-old woman presented with malaise, intermittent fever, weight loss, and epigastric pain. Histoplasma capsulatum was eventually isolated from a liver biopsy and from the bone marrow and the patient was successfully treated with amphotericin B.


Assuntos
Anfotericina B/uso terapêutico , Histoplasmose/tratamento farmacológico , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Biópsia , Medula Óssea/microbiologia , Ensaios Enzimáticos Clínicos , Testes de Fixação de Complemento , Feminino , Febre/etiologia , Hematócrito , Hepatomegalia , Histoplasma/isolamento & purificação , Histoplasmose/diagnóstico , Histoplasmose/patologia , Humanos , Fígado/microbiologia , Fígado/patologia , Pessoa de Meia-Idade , Dor/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...